Synthesis and antibacterial evaluation of some teicoplanin pseudoaglycon derivatives containing alkyl- and arylthiosubstituted maleimides by Csávás, Magdolna et al.
ORIGINAL ARTICLE
Synthesis and antibacterial evaluation of some
teicoplanin pseudoaglycon derivatives containing
alkyl- and arylthiosubstituted maleimides
Magdolna Csávás1, Adrienn Miskovics1, Zsolt Szűcs1, Erzsébet Rőth1, Zsolt L Nagy1, Ilona Bereczki1,
Mihály Herczeg1, Gyula Batta2, Éva Nemes-Nikodém3, Eszter Ostorházi3, Ferenc Rozgonyi3, Anikó Borbás1 and
Pál Herczegh1 Dedicated to the memory of Professor Maria N Preobrazhenskaya✠
Bis-alkylthio maleimido derivatives have been prepared from teicoplanin pseudoaglycon by reaction of its primary amino group
with N-ethoxycarbonyl bis-alkylthiomaleimides. Some of the new derivatives displayed excellent antibacterial activity against
resistant bacteria.
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INTRODUCTION
Glycopeptide antibiotics exert their antibacterial activityQ4 by inhibiting
two sequential enzymatic reactions—transglycosylation and transpep-
tidation—in the bacterial cell-wall biosynthesis. The antibiotics
recognize and tightly bind to the L-Lys-D-Ala- D-Ala termini of
peptidoglycan precursors at the external side of the developing
bacterial membrane. In this way transglycosylation and transpeptida-
tion are physically prevented, arresting cell-wall elongation and cross-
linking and leading to cell lysis.1 Due to the lack of cross-resistance to
other antibacterial drugs, the glycopeptide antibiotics have become
ﬁrst-line drugs for the treatment of life-threatening multi-drug
resistant infections by Gram-positive bacteria.2
The emergence and spread of glycopeptide-resistant enterococci and
glycopeptide intermediate-resistant Staphylococcus aureus, as well as
teicoplanin-resistant Staphylococcus haemolyticus3 present a serious
global challenge and have led to renewed interest in the development
of novel, effective and safe antibacterials including new derivatives of
glycopeptide antibiotics.4–6
Inspired by the high activity of the semisynthetic lipoglycopeptide
antibiotics telavancin,7 dalbavancin8 and oritavancin9 against
vancomycin-resistant bacteria, we have started a program to produce
new antibiotics by introducing lipophilic subtituents to the primary
amino function of ristocetin aglycon and of teicoplanin pseudoagly-
con. Applying various approaches including squaric acid conjugation
method, azide-alkyne cycloaddition reaction or three-component
isoindole formation, we have prepared a large set of new derivatives
exhibiting high antibacterial10–13 and, in some cases, robust anti-
inﬂuenza virus activity.14–17
Recently, Caddick, Baker and coworkers18–21 reported on applica-
tions of 3,4-dibromomaleimides for site-speciﬁc protein modiﬁcation
and bioconjugation. The method is based on addition–elimination
reaction of thiols to the bromomaleimides leading to regeneration of
the double bond resulting in thiomaleimide products (Scheme 1). Last
year the group of Caddick and Baker published a simple method for
the synthesis of N-functionalised bromo- and thiomaleimides through
the corresponding N-ethoxycarbonyl maleimide derivatives.22 Apply-
ing these recent results of maleimide chemistry we describe here
derivatisation of teicoplanin pseudoaglycon with thiomaleimide sub-
stituents carrying two lipophilic alkyl or aryl sulﬁde side chains.
RESULTS AND DISCUSSION
Dibromomaleimide (1) that can be obtained by simple bromination of
maleimide23 has been allowed to react with a range of thiols including
the 6-thio-D-galactose derivative 2a, thiophenol 2b, phenylmetha-
nethiol 2c, dodecanethiol 2d, octanethiol 2e, propanethiol 2f and
t-butyl mercaptane 2h, representing a series of substituents of different
lipophilicity.
The obtained sulﬁdes 3a–g have been then ethoxycarbonylated with
ethyl chloroformate in the presence of potassium carbonate to provide
5a–g, ready for a reaction with a primary amino group (Scheme 2).
Direct methoxycarbonylation12b of dibromomaleimide offers an alter-
native route for the synthesis of the targeted N-functionalized
dithiomaleimide as it is illustrated by the synthesis of 6g. We tested
this route with several thiols such as 2d–2g, however, the sulﬁde
formation showed low efﬁcacy in all cases.
Next, teicoplanin pseudoaglycon 710c has been reacted with
N-ethoxycarbonyl maleimides 5a–g and 6g in the presence of
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triethylamine (Table 1). In these reactions bis-alkyl- or arylthiomalei-
mide 8a–f were formed in moderate yields, together with the N-
alkoxycarbonyl derivatives of the teicoplanin pseudoaglycon (9 and
10). The formation of 9 and 10 can be explained by the steric
hindrance of the amino function of 7. In the case of 5g and 6g, the
undesired carbamate derivatives 9 and 10 were dominantly formed,
probably due to the presence of bulky t-butyl substituents of the
reagents.
Antibacterial activity of maleimido-teicoplanin-pseudoaglycons was
evaluated on a panel of Gram-positive bacteria (Table 2). The D-
galactose-containing 8a, the bis-phenylthio derivative 8b and the bis-
benzylthio derivative 8c displayed similar activities than teicoplanin
pseudoaglycon 7 with one exception: the maleimido compounds 8a–c
were active against Enterococcus faecalis 15 376 having vanA resistance
gene while teicoplanin and 7 were completely inactive against this
bacterium strain.
The detected antibacterial activities of 8d, 8e and 8f were related to
the length of the alkyl chain substituents of their maleimide residues.
The bis-dodecyl derivative 8d was inactive, the bis-octyl derivative 8e
was a weak antibacterial and the bis-propylthio compound 8f
displayed very high activity. It can be supposed that a correlation
exists between lipophilicity of the maleimide substituents and anti-
bacterial activity, and the high lipophilicity erodes the activity. To test
this hypothesis, logP (logarithm of partition coefﬁcient between n-
octanol and water) values were calculated for N-methyl maleimide
derivatives 11a–f and the calculated logP values corroborate our
postulation (Table 3).
In conclusion we have utilized, for the ﬁrst time, bis-sulﬁde
derivatives of N-alkoxycarbonyl maleimide for versatile derivatisation
of teicoplanin pseudoaglycon. It turned out that lipophilicity of
substituents of the maleimide ring has strong inﬂuence on the
antibacterial activity of these derivatives. Further synthetic tuning of




Maleimide and thiols 2b–2g were purchased from Sigma-Aldrich Q5Chemical.
2,3-Dibromomaleimide 1, 1,2:3,4-di-O-isopropylidene-6-deoxy-6-thio-α-D-
galactopyranose 2a and teicoplanin pseudoaglycon 7 were prepared according
to literature procedures. TLC analysis was performed on Kieselgel 60 F254
(Merck Q6) silica gel plates with visualization by immersing in ammonium-
molibdate solution followed by heating or Pauly-reagent in the case of
teicoplanin derivatives. Column chromatography was performed on silica gel
60 (Merck 0.063–0.200mm), ﬂash column chromatography was performed on
silica gel 60 (Merck 0.040–0 0.063mm). Organic solutions were dried over
MgSO4 and concentrated under vacuum. The
1H (400 and 500MHz) and 13C
NMR (100.28, 125.76MHz) spectra were recorded with Bruker DRX-400 and
Bruker Avance II 500 spectrometers. Chemical shifts are referenced to Me4Si or
DSS Q7(0.00 p.p.m. for 1H) and to solvent signals (CDCl3: 77.00 p.p.m., DMSO-
d6: 39.51 p.p.m. for
13C). MALDI Q8-TOF MS analyses for the compounds 8b, 8c,
8e, 9 and 10 were carried out in positive reﬂectron mode using a BIFLEX III
mass spectrometer (Bruker Q9, Germany) equipped with delayed-ion extraction.
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by a Voyager-DE STR MALDI-TOF Biospectrometry Workstation (Applied
BiosystemsQ10 ). 2,5-Dihydroxybenzoic acid was used as matrix and CF3COONa as
cationising agent in DMF. Elemental analysis (C, H, S) was performed on an
Elementar Vario MicroCube instrument. The antibacterial activity of 8a–f, 9
and 10 was tested against a panel of Gram-positive bacteria using broth
microdilution method as described earlier.24
General method A for preparation maleimide bis-sulﬁdes (3a–3g)
To a stirred solution of 2,3-dibromomaleimide23 (1.0mmol) in CH2Cl2 (20ml)
Et3N (2.0 mmol) and thiol (2.1mmol) were added under argon atmosphere
and stirred for 3 h at room temperature. The reaction mixture was evaporated,
and the crude product was puriﬁed by ﬂash chromatography to give the desired
compound.
General method B for preparation N-ethoxycarbonyl maleimide
bis-sulﬁdes (5a–5g)
To a stirred solution of maleimide bis-sulﬁde (1.0mmol) in dry acetone
(20ml) K2CO3 (1.2mmol) and ethyl chloroformate (1.2mmol) were added
under argon atmosphere and stirred for 3 h at room temperature. The
reaction mixture was diluted with CH2Cl2, ﬁltered through a pad of Celite
and evaporated. The crude product was used for further step without
puriﬁcation.
Table 1 Synthesis and structure of teicoplanin pseudoaglycon-maleimide conjugates
Reagent R Products (yield %)
5a 8a (15) 9a
5b Ph 8b (21) 9 (41)
5c Bn 8c (16) 9 (44)
5d n-dodecyl 8d (44) 9a
5e n-octyl 8e (22) 9a
5f n-propyl 8f (66) 9a
5g t-butyl 8gb 9 (59)
6g t-butyl 8gb 10 (48)
aFormation was observed (based on TLC), but it was not isolated.
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General method C for the synthesis of teicoplanin pseudoaglycon
derivatives (8a–8f)
To a stirred solution of teicoplanin pseudoaglycon10c (0.1mmol) in dry DMF
(5ml) N-ethoxycarbonyl maleimide bis-sulﬁdes (0.14mmol) and Et3N (0.1
mmol) were added under argon atmosphere and stirred for overnight at room
temperature. The reaction mixture was evaporated, and the crude product was
puriﬁed by ﬂash chromatography to give the desired compound.
Compound 3a. 2,3-Dibromomaleimide (255mg, 1.0 mmol) was reacted with
thiol 2a25 (580.4mg, 2.1 mmol) according to general method A. The crude
product was puriﬁed by silica gel chromatography in n-hexane:acetone= 8:2, to
give 3a (550mg, 85%) as a yellow sirup. 1H NMR (400MHz, CDCl3) δ 7.58
(1H, s, NH), 5.51 (2H, d, J1,2= 0.3 Hz, 2×H-1), 4.62 (2H, d, J2,3= 8.0 Hz,
2×H-2), 4.32–4.30 (4H, m, 2×H-3, 2×H-4), 3.98–3.95 (2H, m, 2×H-5),
3.57–3.36 (4H, m, 2×H-6a,b), 1.48, 1.44, 1.33, 1.32 (24H, 4× s, 8 ×CH3-ip);
13C NMR (100MHz, CDCl3) δ 165.8 (2C, 2×C=O), 137.2, 136.9 (2C, C=C),
109.5, 108.7 (4C, 4×Cq-ip), 96.5 (2C, 2×C-1), 71.5, 70.9, 70.4, 67.9 (8C,
skeleton carbons), 31.6 (2C, 2×C-6), 25.9, 24.9, 24.4 (8C, 8×CH3); analysis
calculated for C28H39NO12S2 C 52.08, H 6.09, N 2.17, O 29.73, S 9.93. Found:
C 51.99, H 6.08, S 9.90.
Compound 3b. 2,3-Dibromomaleimide (255mg, 1.0mmol) was reacted
with thiophenol 2b (215 μl, 2.1mmol) according to general method A.
The crude product was puriﬁed by silica gel chromatography in n-hexane:
acetone= 8:2, to give 3b (310mg, 98%) as a yellow sirup. 1H NMR
(400MHz, CDCl3) δ 7.83 (1H, s, NH), 7.29–7.17 (10H, m, arom); 13C
NMR (100MHz, CDCl3) δ 166.5 (2C, 2×C=O), 136.8 (2C, C=C), 131.9,
129.1, 128.6 (10C, arom), 128.9 (2C, Cq arom); analysis calculated for
C16H11NO2S2 C 61.32, H 3.54, N 4.47, O 10.21, S 20.46. Found: C 61.15,
H 3.53, S 20.39.
Compound 3c. 2,3-Dibromomaleimide (510mg, 2.0mmol) was reacted with
benzyl mercaptan 2c (490 μl, 4.2mmol) according to general method A. The
crude product was puriﬁed by silica gel chromatography in n-hexane:acetone=
8:2, to give 3c (460mg, 67%) as a yellow sirup. 1H NMR (400MHz, CDCl3) δ
7.78 (1H, s, NH), 7.29–7.26 (10H, m, arom), 4.42 (4H, s, 2 × SCH2);
13C NMR
(100MHz, CDCl3) δ 175.3, 166.3 (2C, 2×C=O), 136.5 (2C, C=C), 128.9,
128.8, 128.7, 127.7 (10C, arom), 36.2 (2C, 2× SCH2); analysis calculated for
C18H15NO2S2 C 63.32, H 4.43, N 4.10, O 9.37, S 18.78. Found: C 63.19, H 4.45,
S 18.69.
Compound 3d. 2,3-Dibromomaleimide (510mg, 2.0 mmol) was reacted with
dodecyl mercaptan 2d (950 μl, 4.2 mmol) according to general method A. The
crude product was puriﬁed by silica gel chromatography in n-hexane:ethyl
acetate= 9:1, to give 3d (670mg, 67%) as a yellow sirup. 1H NMR (400MHz,
CDCl3) δ 7.55 (1H, s, NH), 3.29–3.25 (4H, m, 2× SCH2), 1.64–1.25 (40H, m,
20×CH2), 0.89–0.86 (6H, m, 2 ×CH3);
13C NMR (100MHz, CDCl3) δ 165.8
(2C, 2×C=O), 136.4 (2C, C=C), 31.5, 31.4, 30.2, 29.3, 29.1, 28.9, 28.7, 28.1
(20C, 20×CH2), 22.3 (2C, 2 × SCH2), 13.7 (2C, 2×CH3). Analysis calculated
for C28H51NO2S2 C 67.55, H 10.33, N 2.81, O 6.43, S 12.88. Found: C 66.59, H
10.23, S 12.03.
Compound 3e. 2,3-Dibromomaleimide (255mg, 1.0 mmol) was reacted with
octyl mercaptan 2e (364 μl, 2.1 mmol) according to general method A. The
crude product was puriﬁed by silica gel chromatography in n-hexane:acetone=
8:2, to give 3e (317mg, 82%) as a yellow sirup. 1H NMR (400MHz, CDCl3) δ
7.71 (1H, s, NH), 3.28 (4H, t, J= 7.5 Hz, 2× SCH2), 1.69–1.60 (8H, m,
4×CH2), 1.43–1.27 (20H, m, 10×CH2), 0.88 (6H, t, J= 6.8 Hz, 2 ×CH3); 13C
NMR (100MHz, CDCl3) δ 166.3 (2C, 2×C=O), 136.7 (2C, C=C), 31.8,
30.5, 29.0, 28.5 (12C, 12 ×CH2), 22.6 (2C, 2× SCH2), 14.0 (2C, 2×CH3);
analysis calculated for C20H35NO2S2 C 62.29, H 9.15, N 3.63, O 8.30, S 16.63.
Found: C 61.03, H 9.08, S 16.08.
Compound 3f. 2,3-Dibromomaleimide (510mg, 2.0 mmol) was reacted
with propyl mercaptane 2f (380 μl, 4.2 mmol) according to general
method A. The crude product was puriﬁed by silica gel chromatography in
n-hexane:ethyl acetate= 9:1, to give 3f (430mg, 87%) as a yellow
sirup. 1H NMR (400MHz, CDCl3) δ 7.77 (1H, s, NH), 3.28–3.25 (4H, m,
Table 2 Antibacterial activity of compounds 7–10
Teicoplanin 7 8a 8b 8c 8d 8e 8f 9 10
Bacillus subtilis ATCC 6633 0.5/16 2/16 4/256 4/32 4/32 128/256 32/256 1/256 64/256 8/64
Staphylococcus aureus MSSA ATCC 29213 0.5/2 2/32 4/256 2/16 4./32 64/256 8/64 1/256 16/128 8/64
Staphylococcus aureus MRSA ATCC 33591 0.5/2 1/16 4/256 2/16 4/32 64/256 2/16 1/256 4/64 8/64
Staphylococcus epidermidis bioﬁlm ATCC 35984 2/32 2/32 1/256 1/8 0.5/2 8/256 1/8 0.5/256 4/32 4/64
Enterococcus faecalis ATCC 29212 2/64 4/32 4/256 1/64 0.5/64 8/256 8/256 1/256 8/256 8/256
Staphylococcus epidermidis mecA 16/32 1/32 1/256 2/16 0.5/4 8/256 2/16 0.5/256 4/32 8/64
Enterococcus faecalis 15376 vanA 256/256 256/256 4/256 1/256 0.5/32 128/256 32/256 1/256 16/256 8/256
Enterococcus faecalis ATCC 51299 vanB 4/256 2/32 2/256 2/64 0.5/64 64/256 8/128 1/256 8/128 8/128
Abbreviations: ATCC, American type culture collection; mecA, mecA gene expression in Staphylococcus; MRSA, methicillin resistant Staphylococcus aureus; MSSA, methicillin sensitive
Staphylococcus aureus; vanA +, vanA gene positive; vanB +, vanB gene positive.
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2× SCH2), 1.73–1.66 (4H, m, 2×CH2), 1.06–1.02 (6H, m, 2×CH3);
13C NMR (100MHz, CDCl3) δ 166.3 (2C, 2×C=O), 137.2 (2C, C=C),
33.6 (2C, 2 ×CH2), 23.8 (2C, 2× SCH2), 13.1 (2C, 2×CH3); analysis calculated
for C10H15NO2S2 C 48.95, H 6.16, N 5.71, O 13.04, S 26.14. Found: C 48.18, H
5.70, S 26.01.
Compound 3g. 2,3-Dibromomaleimide (510mg, 2.0 mmol) was reacted with
t-butyl mercaptane 2g (473 μl, 4.2mmol) according to general method A. The
crude product was puriﬁed by silica gel chromatography in n-hexane:ethyl
acetate= 9:1, to give 3g (432mg, 80%) as a yellow sirup. 1H NMR (400MHz,
CDCl3) δ 8.09 (1H, s, NH), 1.54 (18H, s, 6 ×CH3); 13C NMR (100MHz,
CDCl3) δ 166.9 (2C, 2×C=O), 145.3 (2C, C=C), 51.9 (2C, 2× SCq), 32.2
(6C, 6×CH3); analysis calculated for C12H19NO2S2 C 52.71, H 7.00, N 5.12, O
11.70, S 23.46. Found: C 51.66, H 6.93, S 22.89.
Compound 6g. To a stirred solution of 2,3-dibromomaleimide (0.255 g, 1.0
mmol) in tetrahydrofuran (4ml) N-methylmorpholine (76 μl, 1.1 mmol) and
methyl chloroformate (85 μl, 1.1 mmol) were added at 0 °C. When TLC (n-
hexane:acetone= 8:2) showed complete conversion of the starting material
(3 h), the reaction mixture was diluted with CH2Cl2, ﬁltered through a pad of
Celite and evaporated. The obtained crude 4 (0.308 g) was reacted, without
puriﬁcation, with t-butyl mercaptan 2g (237 μl, 2.1mmol) according to general
method A to give compound 6g (0.150 g). The crude product was used for
further step without puriﬁcation.
Compound 8a. Teicoplanin pseudoaglycon (140mg, 0.1mmol) was reacted
with compound 5a (100mg, 0.14mmol) according to general method C. The
crude product was puriﬁed by silica gel chromatography in toluene:methanol=
8:2, to give 8a (30mg, 15%) as a yellow powder. MALDI-TOF MS: [M+Na]
+= 2051.39m/z. Calcd for C94H94Cl2N8O35S2Na 2051.45m/z.
Compound 8b. Teicoplanin pseudoaglycon (140mg 0.1mmol) was reacted
with compound 5b (58mg, 0.14mmol) according to general method C. The
crude product was puriﬁed by silica gel chromatography in toluene:methanol=
8:2, to give 8a (35mg, 21%) as a yellow powder. MALDI-TOF MS: [M+Na]
+= 1719.41m/z. Calcd for C82H66Cl2N8O25S2Na 1719.29m/z.
Compound 8c. Teicoplanin pseudoaglycon (140mg, 0.1 mmol) was reacted
with compound 5c (41mg, 0.14mmol) according to general method C. The
crude product was puriﬁed by silica gel chromatography in toluene:methanol=
7:3, to give 8c (27mg, 16%) as a yellow powder. MALDI-TOF MS: [M+Na]
+= 1747.47m/z. Calcd for C84H70Cl2N8O25S2Na 1747.32m/z.
Compound 8d. Teicoplanin pseudoaglycon (140mg, 0.1mmol) was reacted
with compound 5d (74mg, 0.14mmol) according to general method C. The
crude product was puriﬁed by silica gel chromatography in toluene:methanol=
9:1, to give 8d (85mg, 44%) as a yellow powder. MALDI-TOF MS: [M+Na]
+= 1903.66m/z. Calcd for C94H106Cl2N8O25S2Na 1903.60m/z.
Compound 8e. Teicoplanin pseudoaglycon (140mg, 0.1mmol) was reacted
with compound 5e (69mg, 0.14mmol) according to general method C. The
crude product was puriﬁed by silica gel chromatography in toluene:methanol=
8:2, to give 8d (38mg, 22%) as a yellow powder. MALDI-TOF MS: [M+Na]
+= 1791.64m/z. Calcd for C86H90Cl2N8O25S2Na 1791.47m/z.
Compound 8f. Teicoplanin pseudoaglycon (140mg, 0.1 mmol) was reacted
with compound 5f (40mg, 0.14mmol) according to general method C. The
crude product was puriﬁed by silica gel chromatography in toluene:methanol=
9:1, to give 8d (110mg, 66%) as a yellow powder. MALDI-TOF MS: [M+Na]
+= 1651.02m/z. Calcd for C76H70Cl2N8O25S2Na 1651.32m/z.
Compound 9. Teicoplanin pseudoaglycon (140mg, 0.1mmol) was reacted
with compound 5g (49mg, 0.14mmol) according to general method C. The
crude product was puriﬁed by silica gel chromatography in toluene:methanol=
9:1, to give 9 (87mg, 59%) as a yellow powder. MALDI-TOF MS: [M+Na]
+= 1495.34m/z. Calcd for C69H62Cl2N8O25Na 1495.31m/z.
Compound 10. Teicoplanin pseudoaglycon (210mg, 0.15mmol) was
reacted with compound 6g (70mg, 0.21mmol) according to general
Table 4 1H and 13C NMR data for compounds 8a, 8b, 8c and 8d (chemical shifts in ppm)
Assignment 8a 13C 8a 1H 8b 13C 8b 1H 8c 13C 8c 1H 8d 13C 8d 1H
x1 64.8 7.05 64.8 7.07 64.9 7.06 64.6 7.05
x2 55.6 4.98 55.9 4.98 55.9 4.99 55.5 4.98
x3 59.2 5.32 59.1 5.29 59.2 5.33 59.1 5.36
x4 54.8 5.59 54.8 5.58 54.9 5.59 54.8 5.64
z6 76.8 5.40 76.2 5.45 76.7 5.42 76.3 5.42
2f 131.5 7.68 131.6 7.67 131.5 7.65 131.8 7.69
3b 109.7 6.32 109.7 6.28 110.2 6.32 110.0 6.39
4b 107.9 5.57 108.2 5.53 108.3 5.55 108.2 5.55
4f 104.6 5.07 104.8 5.06 104.9 5.07 104.9 5.06
5b 136.3 7.09 136.6 7.09 136.6 7.09 136.5 7.11
GlcNAc 1 98.4 4.40 98.8 4.39 99.0 4.36 99.0 4.39
Maleimide 2 165.3 165.4 165.4 165.5
Maleimide 3 135.3 135.3 136.8 134.2
Maleimide 4 135.3 135.3 136.8 134.2
Maleimide 5 165.3 165.4 165.4 165.5
SCH2 35.5 4.42–4.37 31.5 3.33–3.21
α-Galp 1 95.7 5.41
α-Galp 2 69.7 4.30
α-Galp 3 70.2 4.60
α-Galp 4 70.9 4.22
α-Galp 5 67.2 3.82
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method C. The crude product was puriﬁed by silica gel chromatography
in toluene:methanol= 8:2, to give 10 (120mg, 48%) as a yellow powder.
MALDI-TOF MS: [M+Na]+= 1481.51m/z. Calcd for C68H60Cl2N8O25Na
1481.29m/z.
NMR analysis
The 1H and 13C NMR data of the teicoplanin derivatives 8a–f, 9 and 10 are
collected in Tables 4 and 5. The spectra were recorded at 500.13/125.76MHz
frequencies, respectively, at 300 K, using DMSO-d6, as solvent. Numbering
Table 5 1H and 13C NMR data for compounds 8e, 8f, 9 and 10 (chemical shifts in p.p.m.)
Assignment 8e 13C 8e 1H 8f 13C 8f 1H 9 13C 9 1H 10 13C 10 1H
x1 64.8 7.05 64.8 7.05 64.8 7.05 64.8 7.06
x2 56.0 4.99 55.7 4.99 55.7 4.98 56.0 4.98
x3 59.4 5.42 59.2 5.42 58.9 5.34 59.3 5.42
x4 54.9 5.57 54.8 5.58 54.8 5.62 54.8 5.59
z6 76.0 5.42 76.2 5.42 76.8 5.42 76.3 5.42
2f 131.3 7.64 131.0 7.64 131.8 7.63 131.5 7.66
3b 110.0 6.32 110.0 6.32 110.0 6.32 109.9 6.33
4b 108.3 5.57 108.1 5.54 107.6 5.53 108.0 5.51
4f 104.8 5.08 104.7 5.08 104.8 5.09 104.8 5.08
5b 136.6 7.09 136.3 7.09 136.2 7.2 136.1 7.09
GlcNAc 1 99.3 4.38 99.4 4.38 99.8 4.36 98.6 4.38
Maleimide 2 165.5 165.4
Maleimide 3 138.5 135.4
Maleimide 4 138.5 135.4
Maleimide 5 165.5 165.4
SCH2 31.0 3.25–3.17 32.9 3.28–3.15
CH2 29.9–21.9 1.56–1.14 23.4 1.60–1.55
CH3 13.8 0.86–0.82 12.8 0.95–0.93
NH 1 7.96
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atoms in teicoplanin derivatives are given in Figure 1. Signal assignments were
aided by 2D HSQC, TOCSY (15 and 60ms mixing times) and HMBC (60ms
mixing time) experiments.
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